Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 768-778

  Stilgenbauer, Stephan ^a   Eichhorst, Barbara ^b   Schetelig, Johannes ^c   Coutre, Steven ^d   Seymour, John F ^e   Munir, Talha ^f   Puvvada, Soham D ^g   Wendtner, Clemens Martin ^h   Roberts, Andrew W ^e   Jurczak, Wojciech ⁱ   Mulligan, Stephen P ^j   Böttcher, Sebastian ^k   Mobasher, Mehrdad ^l   Zhu, Ming ^m   Desai, Monali ^m   Chyla, Brenda ^m   Verdugo, Maria ^m   Enschede, Sari Heitner ^m   Cerri, Elisa ^m   Humerickhouse, Rod ^m   Gordon, Gary ^m   Hallek, Michael ^b   Wierda, William G ⁿ   more..

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF ARIZONA   (United States)

^h Klinikum Schwabing   (Germany)

ⁱ JAGIELLONIAN UNIVERSITY   (Poland)

^j UNIVERSITY OF SYDNEY   (Australia)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l GENENTECH INC   (United States)

^m ABBVIE INC   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VENETOCLAX; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; BRAIN HEMORRHAGE; CANADA; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME DELETION; CHROMOSOME DELETION 17P; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GERMANY; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LOWER RESPIRATORY TRACT INFECTION; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLAND; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHINOPHARYNGITIS; SEPTIC SHOCK; SIDE EFFECT; SKIN CARCINOMA; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADULT; CANCER STAGING; CHROMOSOME 17; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SULFONAMIDES; SURVIVAL RATE;

EID: 84970032000     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30019-5     Document Type: Article

References (30)

1. 1 Eichhorst, B, Robak, T, Montserrat, E, et al., the ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:suppl 5 (2015), v78–v84.
2. 2 Rai, KR, Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol, 8, 2015, 85.
3. 3 Landau, DA, Tausch, E, Taylor-Weiner, AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526 (2015), 525–530.
4. 4 Gaidano, G, Foà, R, Dalla-Favera, R, Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 122 (2012), 3432–3438.
5. 5 Fischer, K, Cramer, P, Busch, R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29 (2011), 3559–3566.
6. 6 Hallek, M, Fischer, K, Fingerle-Rowson, G, et al. the International Group of Investigators, the German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376 (2010), 1164–1174.
7. 7 Dreger, P, Schetelig, J, Andersen, N, et al. the European Research Initiative on CLL (ERIC), the European Society for Blood and Marrow Transplantation (EBMT). Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood 124 (2014), 3841–3849.
8. 8 Byrd, JC, Furman, RR, Coutre, SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125 (2015), 2497–2506.
9. 9 Jain, P, Keating, M, Wierda, W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125 (2015), 2062–2067.
10. 10 Maddocks, KJ, Ruppert, AS, Lozanski, G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1 (2015), 80–87.
11. 11 Burger, JA, Tedeschi, A, Barr, PM, et al., the RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373 (2015), 2425–2437.
12. 12 Furman, RR, Sharman, JP, Coutre, SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370 (2014), 997–1007.
13. 13 Farooqui, MZ, Valdez, J, Martyr, S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16 (2015), 169–176.
14. 14 Marschitz, I, Tinhofer, I, Hittmair, A, Egle, A, Kos, M, Greil, R, Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. Am J Clin Pathol 113 (2000), 219–229.
15. 15 Souers, AJ, Leverson, JD, Boghaert, ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19 (2013), 202–208.
16. 16 Anderson, MA, Tam, CCS, Seymour, JF, et al. Selective Bcl-2 inhibition with ABT-199 is highly active against chronic lymphocytic leukemia (CLL) irrespective of TP53 mutation or dysfunction. Blood, 122, 2013, 1304.
17. 17 Roberts, AW, Davids, MS, Pagel, JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374 (2016), 311–322.
18. 18 Vysis CLL CDx FISH Kit List No. 07N67-020.
19. 19 Hallek, M, Cheson, BD, Catovsky, D, et al., the International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (2008), 5446–5456.
20. 20 Rawstron, AC, Böttcher, S, Letestu, R, et al., the European Research Initiative in CLL. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27 (2013), 142–149.
21. 21 Matutes, E, Owusu-Ankomah, K, Morilla, R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8 (1994), 1640–1645.
22. 22 Garcia, DP, Rooney, MT, Ahmad, E, Davis, BH, Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. Am J Clin Pathol 115 (2001), 258–265.
23. 23 Pettitt, AR, Jackson, R, Carruthers, S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 30 (2012), 1647–1655.
24. 24 Stilgenbauer, S, Zenz, T, Winkler, D, et al., the German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27 (2009), 3994–4001.
25. 25 Wierda, WG, Kipps, TJ, Mayer, J, et al., the Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28 (2010), 1749–1755.
26. 26 Badoux, XC, Keating, MJ, Wang, X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117 (2011), 3016–3024.
27. 27 Strati, P, Keating, MJ, O'Brien, SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123 (2014), 3727–3732.
28. 28 Böttcher, S, Ritgen, M, Fischer, K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30 (2012), 980–988.
29. 29 Leverson, JD, Phillips, DC, Mitten, MJ, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med, 7, 2015, 279ra40.
30. 30 Molica, S, The clinical safety of ibrutinib in chronic lymphocytic leukemia. Expert Opin Drug Saf 14 (2015), 1621–1629.